Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ALLLF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CEACAM5C
|
|||||
| Synonyms |
SGN-CEACAM5C; SAR445953; PF-08046050
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator);Sanofi (Top20 MNC)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
|
|
||||||
| Antibody Name |
Tusamitamab
|
Antibody Info | ||||
| Antigen Name |
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
|
Antigen Info | ||||
| Payload Name |
AMDCPT
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Colorectal cancer |
1 Trials
|
||||||||
| Gastric cancer |
1 Trials
|
||||||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
ADC-specific functional property(2027 Update)
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
Accordingly, the ADC incubated in a co-culture of CEACAM5-positive and -negative cells at a ratio of 1/1 induces a ~50% growth inhibition of CEACAM5-negative cells.
|
[1]
|
References